5yr
Adjuvant Chemotherapy for Low-Clinical-Risk Breast Cancer Defined by Modified Version of Adjuvant! Online: A Propensity Score Matched SEER Analysis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34012370/
This retrospective study provides evidence that CT may not be beneficial to patients 50 years of age or older with HR-positive, HER2-negative, axillary node-negative breast cancer and additionally defined as low clinical risk by a modified version of Adjuvant! Online.
Key Points
• In the current study, researchers retrospectively assessed whether 56 patients with EGFR-mutated lung cancer were effectively be treated with PD-1/PD-L1 therapy plus chemotherapy with or without bevacizumab. These patients had previously received extensive treatment and progressed on EGFR-TKI treatment.
• The authors documented objective responses in 10.7% of patients. Disease was controlled in 53.6% of patients, and the median PFS was months, with no patient exhibiting complete response.
• “Results show that the PD-1 inhibitor-based combination therapy and the EGFR wild-type lung cancer have similar AE [adverse event] profiles,” the authors wrote. “This combination therapy shows longer PFS than the PD-1 inhibitor monotherapy reported before. However, the addition of chemotherapy and/or bevacizumab therapy to the anti-PD-1 therapy did not remarkably improved on heavily treated patients.”